Orphan drugs are medicines developed to treat rare diseases — conditions that affect relatively few people and are often serious, chronic or life-threatening. Because demand for any single rare-disease treatment is small, these medicines are frequently not registered or stocked in a patient's home country, leaving families and clinicians searching across borders for a reliable, compliant supply. GNH USA is a US-based, WHO GDP-certified pharmaceutical distributor that serves patients and healthcare providers worldwide. We source orphan and rare-disease medicines from regulator-approved markets across the globe and arrange their supply wherever the patient is treated, working alongside the clinicians, hospitals and importers who carry local responsibility.
What we supply
Orphan and rare-disease medicines, sourced worldwide
Orphan drugs
Medicines for rare diseases, including those that carry orphan designation from regulators such as the FDA, the EMA and other authorities worldwide.
Biologics and specialty therapies
Complex and specialty products for rare conditions, handled with the care that sensitive formulations require.
Named-patient supply
Access for individual patients to medicines not licensed locally, arranged on a named-patient basis with the treating clinician.
Cold-chain medicines
Temperature-sensitive treatments shipped through validated, monitored lanes to protect product integrity end to end.
Global sourcing
A worldwide network of regulator-approved suppliers, so a suitable source can be identified even for hard-to-find products.
WHO GDP handling
Every shipment is handled under WHO Good Distribution Practice, with the documentation needed to demonstrate a compliant chain.
Rare diseases share a common challenge: the smaller the patient population, the less likely it is that a given treatment will be commercially available in every country. Regulators including the US Food and Drug Administration and the European Medicines Agency operate orphan designation programs to encourage the development of medicines for rare conditions, and similar frameworks exist in other jurisdictions. Even where a medicine has been approved somewhere in the world, however, it may not be registered, stocked or reimbursed in the country where a particular patient is being treated. That gap between approval in one market and availability in another is exactly where a worldwide distributor can help.
GNH USA's role is to sit on the supply side of that gap. We identify a suitable, regulator-approved source for the medicine, handle it under WHO GDP-certified conditions, and deliver it with the documentation a clinician, hospital or importer needs to satisfy the applicable local pathway. The clinical decision to prescribe and the regulatory responsibility for import and use remain with the local parties; we make the global sourcing and logistics dependable so they can focus on the patient.
You can request a medicine at any time, or read more about our named-patient supply service and how we support clinicians and patients worldwide.
The process
From request to delivery
- Step 01
Request
A clinician, hospital, importer or caregiver tells us the orphan or rare-disease medicine required and the clinical context.
- Step 02
Verification
We confirm the order and the documentation that the applicable local pathway requires before anything moves.
- Step 03
Sourcing
We identify a suitable, regulator-approved source for the product from markets worldwide.
- Step 04
Quality assurance
Internal quality checks are completed before release, with handling under WHO GDP throughout.
- Step 05
Delivery
The medicine ships via validated, temperature-controlled lanes to the receiving clinician or institution.
Medicine request
Request an orphan or rare-disease medicine
Sourced worldwide
From regulator-approved markets toward the patient wherever they are treated.
Rare-disease focus
Experience with orphan drugs, biologics and other hard-to-find treatments.
WHO GDP cold-chain
Temperature-sensitive medicines ship via validated, monitored lanes.
Documented supply
Each shipment is supported by the documentation a compliant route requires.
Request a medicine
FAQ
Frequently asked questions
What is an orphan drug?
An orphan drug is a medicine developed to treat a rare disease — a condition that affects a relatively small number of people and is often serious or life-threatening. Regulators such as the US Food and Drug Administration and the European Medicines Agency operate orphan designation programs to encourage the development of these treatments, and similar frameworks exist in other jurisdictions.
Why are orphan drugs hard to find locally?
Because each rare disease affects relatively few patients, demand for any single treatment is small. As a result, an orphan drug may be approved in one market but not registered, stocked or reimbursed in the country where a particular patient is being treated. That gap between approval in one place and availability in another is where a worldwide distributor can help.
How does GNH USA source orphan and rare-disease medicines?
GNH USA is a US-based, WHO GDP-certified distributor that sources orphan, rare-disease and other hard-to-find medicines from regulator-approved markets worldwide, then arranges compliant, temperature-controlled delivery to the patient's clinician or institution with full documentation.
Who can request an orphan drug?
Requests are made in connection with the treating clinician and the receiving hospital or importer, who take clinical and regulatory responsibility locally. Caregivers and pharmacies can start an enquiry, and the supply proceeds in line with the applicable local pathway.
How is named-patient supply related to orphan drugs?
Named-patient supply is a route through which an individual patient can access a medicine that is not licensed in their own country, arranged on a per-patient basis with the treating clinician. It is often used for orphan and rare-disease treatments that are unavailable locally. You can read more on our named-patient supply page.
How long does the process take?
Timelines depend on the medicine, its source, the local pathway and the documentation involved. We respond to enquiries within one business day and confirm the expected route once the request is verified.
Related
Other services
Comparator Sourcing for Clinical Trials
Reference-listed drug and active comparator supply for clinical trials worldwide — direct from manufacturer, with WHO GDP-compliant logistics.
Clinical Trials Supply
End-to-end IMP sourcing, kitting and depot-to-site logistics — GDP-compliant warehousing, manufacturer relationships and a full source-to-site audit trail.
Validated Cold Chain Shipment
WHO GDP-validated cold-chain shipping for biologics, vaccines and temperature-sensitive medicines — qualified boxes and en-route temperature monitoring.